Ocular Total Current Assets vs Net Invested Capital Analysis
OCUL Stock | USD 10.06 0.31 3.18% |
Ocular Therapeutix financial indicator trend analysis is much more than just breaking down Ocular Therapeutix prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ocular Therapeutix is a good investment. Please check the relationship between Ocular Therapeutix Total Current Assets and its Net Invested Capital accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocular Therapeutix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.
Total Current Assets vs Net Invested Capital
Total Current Assets vs Net Invested Capital Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ocular Therapeutix Total Current Assets account and Net Invested Capital. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Ocular Therapeutix's Total Current Assets and Net Invested Capital is 0.9. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Net Invested Capital in the same time period over historical financial statements of Ocular Therapeutix, assuming nothing else is changed. The correlation between historical values of Ocular Therapeutix's Total Current Assets and Net Invested Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of Ocular Therapeutix are associated (or correlated) with its Net Invested Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Invested Capital has no effect on the direction of Total Current Assets i.e., Ocular Therapeutix's Total Current Assets and Net Invested Capital go up and down completely randomly.
Correlation Coefficient | 0.9 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Total Current Assets
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.Net Invested Capital
The total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents.Most indicators from Ocular Therapeutix's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ocular Therapeutix current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocular Therapeutix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.The value of Selling General Administrative is expected to slide to about 19 M. The value of Issuance Of Capital Stock is estimated to slide to about 9.1 M
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 6.7M | 7.0M | 11.3M | 11.9M | Depreciation And Amortization | 2.4M | 2.1M | 3.0M | 1.6M |
Ocular Therapeutix fundamental ratios Correlations
Click cells to compare fundamentals
Ocular Therapeutix Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Ocular Therapeutix fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 78.7M | 261.9M | 204.9M | 149.3M | 252.1M | 126.8M | |
Short Long Term Debt Total | 59.3M | 58.4M | 59.0M | 64.3M | 83.4M | 87.6M | |
Other Current Liab | 7.6M | 12.9M | 18.5M | 22.5M | 27.1M | 28.4M | |
Total Current Liabilities | 12.0M | 26.7M | 26.3M | 31.4M | 34.9M | 36.6M | |
Total Stockholder Equity | (3.6M) | 76.1M | 88.0M | 35.4M | 91.1M | 95.7M | |
Other Liab | 12.1M | 110.3M | 33.2M | 19.8M | 22.8M | 18.3M | |
Property Plant And Equipment Net | 16.8M | 13.9M | 11.8M | 17.9M | 18.2M | 10.0M | |
Net Debt | 4.9M | (169.6M) | (105.2M) | (38.0M) | (112.4M) | (106.8M) | |
Retained Earnings | (383.6M) | (539.3M) | (545.8M) | (616.8M) | (697.6M) | (662.7M) | |
Accounts Payable | 3.3M | 2.7M | 4.6M | 5.1M | 4.4M | 3.0M | |
Cash | 54.4M | 228.1M | 164.2M | 102.3M | 195.8M | 205.6M | |
Non Current Assets Total | 18.6M | 15.7M | 13.6M | 19.7M | 19.8M | 11.8M | |
Other Assets | 1.6M | 6.6M | 1.8M | 7.6M | 1.0 | 0.95 | |
Long Term Debt | 49.3M | 41.2M | 51.4M | 54.0M | 74.9M | 78.7M | |
Cash And Short Term Investments | 54.4M | 228.1M | 164.2M | 102.3M | 195.8M | 103.6M | |
Net Receivables | 2.5M | 12.3M | 21.1M | 21.3M | 26.2M | 27.5M | |
Common Stock Shares Outstanding | 45.3M | 60.8M | 82.2M | 76.9M | 85.6M | 44.2M | |
Liabilities And Stockholders Equity | 78.7M | 261.9M | 204.9M | 149.3M | 252.1M | 126.8M | |
Non Current Liabilities Total | 70.3M | 159.1M | 90.6M | 82.5M | 126.0M | 69.6M | |
Other Current Assets | 2.2M | 8.0M | 9.5M | 4.0M | 7.9M | 8.3M | |
Other Stockholder Equity | 380.0M | 615.3M | 633.8M | 652.2M | 788.7M | 828.1M | |
Total Liab | 82.4M | 185.8M | 116.9M | 113.9M | 160.9M | 86.2M | |
Property Plant And Equipment Gross | 16.8M | 13.9M | 11.8M | 17.9M | 38.5M | 40.4M | |
Total Current Assets | 60.2M | 246.2M | 191.3M | 129.6M | 232.2M | 243.8M | |
Property Plant Equipment | 10.2M | 8.1M | 11.8M | 9.9M | 11.3M | 7.1M | |
Net Tangible Assets | (3.6M) | 76.1M | 88.0M | 35.4M | 31.8M | 40.7M | |
Retained Earnings Total Equity | (383.6M) | (539.3M) | (545.8M) | (616.8M) | (555.2M) | (527.4M) | |
Long Term Debt Total | 49.3M | 41.2M | 51.4M | 54.0M | 62.1M | 33.7M | |
Capital Surpluse | 380.0M | 615.3M | 633.8M | 652.2M | 750.0M | 424.2M | |
Inventory | 954K | 1.2M | 1.3M | 2.0M | 2.3M | 2.4M | |
Deferred Long Term Liab | 12.1M | 98.3M | 20.2M | 6.4M | 7.3M | 6.9M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocular Therapeutix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocular Therapeutix. If investors know Ocular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocular Therapeutix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.29) | Revenue Per Share 0.529 | Quarterly Revenue Growth 0.083 | Return On Assets (0.22) | Return On Equity (0.73) |
The market value of Ocular Therapeutix is measured differently than its book value, which is the value of Ocular that is recorded on the company's balance sheet. Investors also form their own opinion of Ocular Therapeutix's value that differs from its market value or its book value, called intrinsic value, which is Ocular Therapeutix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocular Therapeutix's market value can be influenced by many factors that don't directly affect Ocular Therapeutix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocular Therapeutix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocular Therapeutix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocular Therapeutix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.